Merck Millipore launches Mobius CellReady 50 L bioreactor

Published: 15-Mar-2012
Manufacturing Pharmaceutical

Single-use bioreactor offering now includes 3 L to 200 L products

Merck Millipore has expanded its Mobius CellReady Bioreactor product range with the addition of a 50 L single-use stirred tank bioreactor for process development and pilot scale mammalian cell culture.

The 50 L bioreactor extends the company’s portfolio of single-use processing systems from cell culture to ultrafiltration/diafiltration.

Merck Millipore says Mobius SensorReady technology monitors and controls the 50 L bioreactor, offering the flexibility to configure process monitoring at the point of use, reducing the need to customise bioreactor process containers and enabling easy integration of new sensor technologies.

The bioreactor process container features a rigid base and top panel design for simple, reliable and robust installation.

The Mobius CellReady Bioreactor system is available as a turnkey system complete with Finesse automation or as a modular system that can be integrated with a customer’s platform of choice.

‘The Mobius CellReady 50 L bioreactor is an important addition to the Mobius family. We’ve integrated a number of innovative features that deliver ease of use, reliability and operational flexibility compared with existing single-use systems,’ said Paul Chapman, vice president of Biopharm Process Solutions.

‘With this introduction, biopharmaceutical manufacturers now have a wider range of scalable single-use bioreactors offered by Merck Millipore, from three litres to 200 litres, to support their needs from process development to clinical scale.’

  • Companies:
  • Merck Group
See more

You may also like

Manufacturing

MilliporeSigma invests $25m into cell culture media

Read more
The subsidiary of Merck has announced the expansion of its facility in Lenexa, Kansas, adding 98,000 sqft of lab space in the process

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
  3. New 800 sqm microbiology quality laboratory at Aenova Latina site The project adds approximately 500 square meters of new laboratory space, bringing the total to around 800 square meters, and marks a major milestone in the site’s development
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

MilliporeSigma invests $25m into cell culture media

The subsidiary of Merck has announced the expansion of its facility in Lenexa, Kansas, adding 98,000 sqft of lab space in the process
Manufacturing

Improving the operational efficiency of single-use assemblies in liquid bioprocessing

Merck recently announced the launch of its Ultimus Single-Use Process Container Film, which has been designed to provide extreme durability and leak resistance for the single-use assemblies used during bioprocessing liquid applications. Dr Kevin Robinson spoke to Greg Verni, Head of Single-Use and Systems, to find out more
Manufacturing

Merck opens commercial facility in France

The Martillac facility is designed to operate at the highest levels of efficiency and can rapidly pivot from 200 to 2000 litres of drug substance
Manufacturing

MilliporeSigma adds full viral vector contract services with new platform

This new launch has made it one of the first CDMOs and technology developers to provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development
Manufacturing

Merck opens $63m CDMO facility to handle HPAPIs

The industry expert has announced that its Life Science business sector has doubled its highly potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of this facility
Manufacturing

Merck expands technology and capacity for ADC manufacturing

“ADCs have experienced remarkable growth, with commercially approved ADCs tripling in the past three years”
Manufacturing

Merck launches bioprocessing 4.0 platform

The ProCellics Raman Analyzer and Bio4C Pat Raman software provide a module to build robust chemometric models
Subscribe now